{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:46:04Z","timestamp":1793907964695,"version":"4.8.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40265-020-01359-z","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T15:03:55Z","timestamp":1595257435000},"page":"1309-1318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":154,"title":["Inhaled Liposomal Antimicrobial Delivery in Lung Infections"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0145-9740","authenticated-orcid":false,"given":"Matteo","family":"Bassetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Peghin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,20]]},"reference":[{"issue":"11","key":"1359_CR1","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","volume":"37","author":"LM Weiner","year":"2016","unstructured":"Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, Edwards JR, Sievert DM. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011\u20132014. Infect Control Hosp Epidemiol. 2016;37(11):1288\u2013301.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"7","key":"1359_CR2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/14740338.2018.1488962","volume":"17","author":"M Bassetti","year":"2018","unstructured":"Bassetti M, Russo A, Carnelutti A, La Rosa A, Righi E. Antimicrobial resistance and treatment: an unmet clinical safety need. Expert Opin Drug Saf. 2018;17(7):669\u201380.","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"1359_CR3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/17512433.2019.1619454","volume":"12","author":"J Rello","year":"2019","unstructured":"Rello J, Parisella FR, Perez A. Alternatives to antibiotics in an era of difficult-to-treat resistance: new insights. Expert Rev Clin Pharmacol. 2019;12(7):635\u201342.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"1359_CR4","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/clind\/15.4.654","volume":"15","author":"JA Karlowsky","year":"1992","unstructured":"Karlowsky JA, Zhanel GG. Concepts on the use of liposomal antimicrobial agents: applications for aminoglycosides. Clin Infect Dis. 1992;15(4):654\u201367.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1359_CR5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4155\/tde.14.13","volume":"5","author":"M Alipour","year":"2014","unstructured":"Alipour M, Suntres ZE. Liposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa. Therap Deliv. 2014;5(4):409\u201327.","journal-title":"Therap Deliv"},{"issue":"1","key":"1359_CR6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1556-276X-8-102","volume":"8","author":"A Akbarzadeh","year":"2013","unstructured":"Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, Samiei M, Kouhi M, Nejati-Koshki K. Liposome: classification, preparation, and applications. Nanosc Res Lett. 2013;8(1):102.","journal-title":"Nanosc Res Lett"},{"issue":"1","key":"1359_CR7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcf.2016.10.001","volume":"16","author":"AC Bos","year":"2017","unstructured":"Bos AC, Passe KM, Mouton JW, Janssens HM, Tiddens HA. The fate of inhaled antibiotics after deposition in cystic fibrosis: how to get drug to the bug? J Cyst Fibrosis. 2017;16(1):13\u201323.","journal-title":"J Cyst Fibrosis"},{"key":"1359_CR8","first-page":"20","volume":"20","author":"DA Sweeney","year":"2019","unstructured":"Sweeney DA, Kalil AC. Why Don't We have more inhaled antibiotics to treat ventilator-associated pneumonia? Clin Microbial Infection. 2019;20:20.","journal-title":"Clin Microbial Infection"},{"issue":"5","key":"1359_CR9","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/09031936.00090314","volume":"44","author":"HA Tiddens","year":"2014","unstructured":"Tiddens HA, Bos AC, Mouton JW, Devadason S, Janssens HM. Inhaled antibiotics: dry or wet? Eur Respire J. 2014;44(5):1308\u201318.","journal-title":"Eur Respire J"},{"issue":"3","key":"1359_CR10","doi-asserted-by":"crossref","first-page":"e0118454","DOI":"10.1371\/journal.pone.0118454","volume":"10","author":"AC Bos","year":"2015","unstructured":"Bos AC, van Holsbeke C, de Backer JW, van Westreenen M, Janssens HM, Vos WG, Tiddens HA. Patient-specific modeling of regional antibiotic concentration levels in airways of patients with cystic fibrosis: are we dosing high enough? PLoS\u00a0One. 2015;10(3):e0118454.","journal-title":"PLoS\u00a0One"},{"issue":"5","key":"1359_CR11","doi-asserted-by":"crossref","first-page":"e5724","DOI":"10.1371\/journal.pone.0005724","volume":"4","author":"M Alipour","year":"2009","unstructured":"Alipour M, Suntres ZE, Halwani M, Azghani AO, Omri A. Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis. PLoS\u00a0One. 2009;4(5):e5724.","journal-title":"PLoS\u00a0One"},{"key":"1359_CR12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fimmu.2018.00155","volume":"9","author":"R Nisini","year":"2018","unstructured":"Nisini R, Poerio N, Mariotti S, De Santis F, Fraziano M. The multirole of liposomes in therapy and prevention of infectious diseases. Front Immunol. 2018;9:155.","journal-title":"Front Immunol"},{"issue":"1","key":"1359_CR13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13613-016-0140-x","volume":"6","author":"M Bassetti","year":"2016","unstructured":"Bassetti M, Luyt CE, Nicolau DP, Pugin J. Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Ann Intensive Care. 2016;6(1):35.","journal-title":"Ann Intensive Care"},{"issue":"9","key":"1359_CR14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/thoraxjnl-2012-202230","volume":"68","author":"JP Clancy","year":"2013","unstructured":"Clancy JP, Dupont L, Konstan MW, Billings J, Fustik S, Goss CH, Lymp J, Minic P, Quittner AL, Rubenstein RC, et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax. 2013;68(9):818\u201325.","journal-title":"Thorax"},{"issue":"4","key":"1359_CR15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1586\/17476348.2014.918507","volume":"8","author":"V Waters","year":"2014","unstructured":"Waters V, Ratjen F. Inhaled liposomal amikacin. Expert review of respiratory medicine. 2014;8(4):401\u20139.","journal-title":"Expert review of respiratory medicine"},{"issue":"1","key":"1359_CR16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/tri.12679","volume":"29","author":"M Peghin","year":"2016","unstructured":"Peghin M, Monforte V, Martin-Gomez MT, Ruiz-Camps I, Berastegui C, Saez B, Riera J, Ussetti P, Sole J, Gavalda J, et al. 10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation. Transpl Int. 2016;29(1):51\u201362.","journal-title":"Transpl Int"},{"issue":"1","key":"1359_CR17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/tid.12492","volume":"18","author":"M Peghin","year":"2016","unstructured":"Peghin M, Monforte V, Martin-Gomez MT, Ruiz-Camps I, Berastegui C, Saez B, Riera J, Sole J, Gavalda J, Roman A. Epidemiology of invasive respiratory disease caused by emerging non-Aspergillus molds in lung transplant recipients. Transplant Infect Dis. 2016;18(1):70\u20138.","journal-title":"Transplant Infect Dis"},{"issue":"Suppl 2","key":"1359_CR18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000445116","volume":"25","author":"M Rudokas","year":"2016","unstructured":"Rudokas M, Najlah M, Alhnan MA, Elhissi A. Liposome delivery systems for inhalation: a critical review highlighting formulation issues and anticancer applications. Med Principles Pract. 2016;25(Suppl 2):60\u201372.","journal-title":"Med Principles Pract"},{"issue":"1\u20132","key":"1359_CR19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ijpharm.2013.11.022","volume":"461","author":"M Najlah","year":"2014","unstructured":"Najlah M, Parveen I, Alhnan MA, Ahmed W, Faheem A, Phoenix DA, Taylor KM, Elhissi A. The effects of suspension particle size on the performance of air-jet, ultrasonic and vibrating-mesh nebulisers. Int J Pharm. 2014;461(1\u20132):234\u201341.","journal-title":"Int J Pharm"},{"issue":"3","key":"1359_CR20","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.ejpb.2014.10.009","volume":"88","author":"B Lehofer","year":"2014","unstructured":"Lehofer B, Bloder F, Jain PP, Marsh LM, Leitinger G, Olschewski H, Leber R, Olschewski A, Prassl R. Impact of atomization technique on the stability and transport efficiency of nebulized liposomes harboring different surface characteristics. Eur J Pharm Biopharm. 2014;88(3):1076\u201385.","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"1359_CR21","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratala J, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61\u2013e111.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"1359_CR22","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.2217\/fmb.15.117","volume":"10","author":"Z Ehsan","year":"2015","unstructured":"Ehsan Z, Clancy JP. Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin. Future Microbiol. 2015;10(12):1901\u201312.","journal-title":"Future Microbiol"},{"issue":"9","key":"1359_CR23","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/17476348.2018.1503540","volume":"12","author":"S Paredes Aller","year":"2018","unstructured":"Paredes Aller S, Quittner AL, Salathe MA, Schmid A. Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis\u2014experiences from recent clinical trials. Expert Rev Respir Med. 2018;12(9):769\u201382.","journal-title":"Expert Rev Respir Med"},{"key":"1359_CR24","first-page":"CD001021","volume":"3","author":"S Smith","year":"2018","unstructured":"Smith S, Rowbotham NJ, Regan KH. Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev. 2018;3:CD001021.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"1359_CR25","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-2600(19)30185-7","volume":"7","author":"IF Laska","year":"2019","unstructured":"Laska IF, Crichton ML, Shoemark A, Chalmers JD. The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. Lancet Respir Med. 2019;7(10):855\u201369.","journal-title":"Lancet Respir Med"},{"key":"1359_CR26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1183\/13993003.00629-2017","volume":"50","author":"E Polverino","year":"2017","unstructured":"Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Canton R, Torres A, Dimakou K, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50:3.","journal-title":"Eur Respir J"},{"issue":"3","key":"1359_CR27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1128\/CMR.00101-15","volume":"29","author":"E Wenzler","year":"2016","unstructured":"Wenzler E, Fraidenburg DR, Scardina T, Danziger LH. Inhaled antibiotics for gram-negative respiratory infections. Clin Microbiol Rev. 2016;29(3):581\u2013632.","journal-title":"Clin Microbiol Rev"},{"issue":"9","key":"1359_CR28","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cmi.2017.04.011","volume":"23","author":"J Rello","year":"2017","unstructured":"Rello J, Sole-Lleonart C, Rouby JJ, Chastre J, Blot S, Poulakou G, Luyt CE, Riera J, Palmer LB, Pereira JM, et al. Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clin Microbial Infect. 2017;23(9):629\u201339.","journal-title":"Clin Microbial Infect"},{"issue":"3","key":"1359_CR29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1513\/AnnalsATS.201311-395FR","volume":"11","author":"BS Quon","year":"2014","unstructured":"Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc. 2014;11(3):425\u201334.","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"1359_CR30","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1183\/09031936.00201012","volume":"42","author":"H Suhling","year":"2013","unstructured":"Suhling H, Rademacher J, Greer M, Haverich A, Warnecke G, Gottlieb J, Welte T. Inhaled colistin following lung transplantation in colonised cystic fibrosis patients. Eur Respire J. 2013;42(2):542\u20134.","journal-title":"Eur Respire J"},{"issue":"1","key":"1359_CR31","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1600-6143.2005.01145.x","volume":"6","author":"I Ruiz","year":"2006","unstructured":"Ruiz I, Gavalda J, Monforte V, Len O, Roman A, Bravo C, Ferrer A, Tenorio L, Roman F, Maestre J, et al. Donor-to-host transmission of bacterial and fungal infections in lung transplantation. Am J Transplant. 2006;6(1):178\u201382.","journal-title":"Am J Transplant"},{"issue":"10","key":"1359_CR32","doi-asserted-by":"crossref","first-page":"819","DOI":"10.4155\/tde-2017-0050","volume":"8","author":"D Traini","year":"2017","unstructured":"Traini D, Young PM. Drug delivery for tuberculosis: is inhaled therapy the key to success? Therap Deliv. 2017;8(10):819\u201321.","journal-title":"Therap Deliv"},{"issue":"12","key":"1359_CR33","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","volume":"198","author":"DE Griffith","year":"2018","unstructured":"Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study. Am J Respire Crit Care Med. 2018;198(12):1559\u201369.","journal-title":"Am J Respire Crit Care Med"},{"key":"1359_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics8010006","volume":"8","author":"D Cipolla","year":"2016","unstructured":"Cipolla D, Blanchard J, Gonda I. Development of liposomal ciprofloxacin to treat lung infections. Pharmaceutics. 2016;8:1.","journal-title":"Pharmaceutics"},{"key":"1359_CR35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fmicb.2017.00091","volume":"8","author":"KA Hamblin","year":"2017","unstructured":"Hamblin KA, Armstrong SJ, Barnes KB, Davies C, Laws T, Blanchard JD, Harding SV, Atkins HS. Inhaled liposomal ciprofloxacin protects against a lethal infection in a murine model of pneumonic plague. Front Microbiol. 2017;8:91.","journal-title":"Front Microbiol"},{"issue":"4","key":"1359_CR36","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/evj.12309","volume":"47","author":"AJ Burton","year":"2015","unstructured":"Burton AJ, Giguere S, Arnold RD. Pharmacokinetics, pulmonary disposition and tolerability of liposomal gentamicin and free gentamicin in foals. Equine Vet J. 2015;47(4):467\u201372.","journal-title":"Equine Vet J"},{"issue":"5","key":"1359_CR37","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1128\/AAC.06145-11","volume":"56","author":"L Garcia-Contreras","year":"2012","unstructured":"Garcia-Contreras L, Muttil P, Fallon JK, Kabadi M, Gerety R, Hickey AJ. Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs. Antimicrob Agents Chemother. 2012;56(5):2612\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1\u20132","key":"1359_CR38","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijpharm.2005.12.031","volume":"311","author":"M Ricci","year":"2006","unstructured":"Ricci M, Giovagnoli S, Blasi P, Schoubben A, Perioli L, Rossi C. Development of liposomal capreomycin sulfate formulations: effects of formulation variables on peptide encapsulation. Int J Pharm. 2006;311(1\u20132):172\u201381.","journal-title":"Int J Pharm"},{"issue":"3","key":"1359_CR39","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/713840401","volume":"10","author":"OR Justo","year":"2003","unstructured":"Justo OR, Moraes AM. Incorporation of antibiotics in liposomes designed for tuberculosis therapy by inhalation. Drug Deliv. 2003;10(3):201\u20137.","journal-title":"Drug Deliv"},{"issue":"6","key":"1359_CR40","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ijantimicag.2013.07.009","volume":"42","author":"J He","year":"2013","unstructured":"He J, Abdelraouf K, Ledesma KR, Chow DS, Tam VH. Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model. Int J Antimicrob Agents. 2013;42(6):559\u201364.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"1359_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbm.b.31608","volume":"94","author":"G Chimote","year":"2010","unstructured":"Chimote G, Banerjee R. In vitro evaluation of inhalable isoniazid-loaded surfactant liposomes as an adjunct therapy in pulmonary tuberculosis. J Biomed Mater Res B Appl Biomater. 2010;94(1):1\u201310.","journal-title":"J Biomed Mater Res B Appl Biomater"},{"issue":"4","key":"1359_CR42","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4103\/0970-2113.159559","volume":"32","author":"JS Patil","year":"2015","unstructured":"Patil JS, Devi VK, Devi K, Sarasija S. A novel approach for lung delivery of rifampicin-loaded liposomes in dry powder form for the treatment of tuberculosis. Lung India. 2015;32(4):331\u20138.","journal-title":"Lung India"},{"issue":"9","key":"1359_CR43","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1128\/AAC.00872-08","volume":"53","author":"OO Okusanya","year":"2009","unstructured":"Okusanya OO, Bhavnani SM, Hammel J, Minic P, Dupont LJ, Forrest A, Mulder GJ, Mackinson C, Ambrose PG, Gupta R. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother. 2009;53(9):3847\u201354.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1359_CR44","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/jac\/dkn059","volume":"61","author":"P Meers","year":"2008","unstructured":"Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, Kurumunda R, Mackinson C, James G, Fisher S, Perkins WR. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother. 2008;61(4):859\u201368.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"1359_CR45","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/jamp.2008.0693","volume":"22","author":"J Weers","year":"2009","unstructured":"Weers J, Metzheiser B, Taylor G, Warren S, Meers P, Perkins WR. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J Aerosol Med Pulmon Drug Deliv. 2009;22(2):131\u20138.","journal-title":"J Aerosol Med Pulmon Drug Deliv"},{"issue":"3","key":"1359_CR46","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/jamp.2008.0686","volume":"21","author":"Z Li","year":"2008","unstructured":"Li Z, Zhang Y, Wurtz W, Lee JK, Malinin VS, Durwas-Krishnan S, Meers P, Perkins WR. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J Aerosol Med Pulmon Drug Deliv. 2008;21(3):245\u201354.","journal-title":"J Aerosol Med Pulmon Drug Deliv"},{"issue":"2","key":"1359_CR47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","volume":"17","author":"C Castellani","year":"2018","unstructured":"Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibrosis. 2018;17(2):153\u201378.","journal-title":"J Cyst Fibrosis"},{"issue":"4","key":"1359_CR48","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1034\/j.1399-3003.2000.16d30.x","volume":"16","author":"G Doring","year":"2000","unstructured":"Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, Touw DJ. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000;16(4):749\u201367.","journal-title":"Eur Respir J"},{"key":"1359_CR49","first-page":"20","volume":"20","author":"D Bilton","year":"2019","unstructured":"Bilton D, Pressler T, Fajac I, Clancy JP, Sands D, Minic P, Cipolli M, Galeva I, Sole A, Quittner AL, et al. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Cyst Fibrosis. 2019;20:20.","journal-title":"J Cyst Fibrosis"},{"key":"1359_CR50","unstructured":"Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria. US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01315236"},{"issue":"4","key":"1359_CR51","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/jac\/dkm289","volume":"60","author":"M Halwani","year":"2007","unstructured":"Halwani M, Mugabe C, Azghani AO, Lafrenie RM, Kumar A, Omri A. Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia. J Antimicrob Chemother. 2007;60(4):760\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"1359_CR52","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/jac\/dkg317","volume":"52","author":"JF Marier","year":"2003","unstructured":"Marier JF, Brazier JL, Lavigne J, Ducharme MP. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. J Antimicrob Chemother. 2003;52(2):247\u201352.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"1359_CR53","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/mutage\/gep053","volume":"25","author":"N Gungor","year":"2010","unstructured":"Gungor N, Knaapen AM, Munnia A, Peluso M, Haenen GR, Chiu RK, Godschalk RW, van Schooten FJ. Genotoxic effects of neutrophils and hypochlorous acid. Mutagenesis. 2010;25(2):149\u201354.","journal-title":"Mutagenesis"},{"key":"1359_CR54","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jconrel.2014.07.061","volume":"195","author":"K Forier","year":"2014","unstructured":"Forier K, Messiaen AS, Raemdonck K, Nelis H, De Smedt S, Demeester J, Coenye T, Braeckmans K. Probing the size limit for nanomedicine penetration into Burkholderia multivorans and Pseudomonas aeruginosa biofilms. J Control Release. 2014;195:21\u20138.","journal-title":"J Control Release"},{"issue":"5","key":"1359_CR55","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jcf.2015.02.005","volume":"14","author":"V Waters","year":"2015","unstructured":"Waters V, Smyth A. Cystic fibrosis microbiology: advances in antimicrobial therapy. J Cyst Fibros. 2015;14(5):551\u201360.","journal-title":"J Cyst Fibros"},{"key":"1359_CR56","doi-asserted-by":"crossref","unstructured":"Banaschewski B, Hofmann T: Inhaled Antibiotics for Mycobacterial Lung Disease. Pharmaceutics 2019, 11(7).","DOI":"10.3390\/pharmaceutics11070352"},{"key":"1359_CR57","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ijpharm.2019.05.068","volume":"566","author":"I Khatib","year":"2019","unstructured":"Khatib I, Khanal D, Ruan J, Cipolla D, Dayton F, Blanchard JD, Chan HK. Ciprofloxacin nanocrystals liposomal powders for controlled drug release via inhalation. Int J Pharm. 2019;566:641\u201351.","journal-title":"Int J Pharm"},{"key":"1359_CR58","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.00440-18","volume":"62","author":"JD Blanchard","year":"2018","unstructured":"Blanchard JD, Elias V, Cipolla D, Gonda I, Bermudez LE. Effective treatment of Mycobacterium avium subsp. hominissuis and Mycobacterium abscessus species infections in macrophages, biofilm, and mice by using liposomal ciprofloxacin. Antimicrob Agents Chemother. 2018;62:10.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1359_CR59","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","volume":"68","author":"DJ Serisier","year":"2013","unstructured":"Serisier DJ, Bilton D, De Soyza A, Thompson PJ, Kolbe J, Greville HW, Cipolla D, Bruinenberg P, Gonda I. investigators O-: Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax. 2013;68(9):812\u20137.","journal-title":"Thorax"},{"issue":"1","key":"1359_CR60","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/jamp.2007.0652","volume":"21","author":"BK Rubin","year":"2008","unstructured":"Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv. 2008;21(1):71\u20136.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"7","key":"1359_CR61","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","volume":"186","author":"JD Chalmers","year":"2012","unstructured":"Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012;186(7):657\u201365.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"1359_CR62","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","volume":"7","author":"CS Haworth","year":"2019","unstructured":"Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, Thompson B, Wanner A, O'Donnell AE. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. Lancet Respir Med. 2019;7(3):213\u201326.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"1359_CR63","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12281-010-0011-0","volume":"4","author":"J Le","year":"2010","unstructured":"Le J, Schiller DS. Aerosolized delivery of antifungal agents. Curr Fungal Infect Rep. 2010;4(2):96\u2013102.","journal-title":"Curr Fungal Infect Rep"},{"issue":"9","key":"1359_CR64","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1016\/j.transproceed.2008.09.020","volume":"40","author":"JM Borro","year":"2008","unstructured":"Borro JM, Sole A, de la Torre M, Pastor A, Fernandez R, Saura A, Delgado M, Monte E, Gonzalez D. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transpl Proc. 2008;40(9):3090\u20133.","journal-title":"Transpl Proc"},{"issue":"7","key":"1359_CR65","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1128\/AAC.49.7.3028-3030.2005","volume":"49","author":"J Gavalda","year":"2005","unstructured":"Gavalda J, Martin MT, Lopez P, Gomis X, Ramirez JL, Rodriguez D, Len O, Puigfel Y, Ruiz I, Pahissa A. Efficacy of nebulized liposomal amphotericin B in treatment of experimental Pulmonary aspergillosis. Antimicrob Agents Chemother. 2005;49(7):3028\u201330.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1359_CR66","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.healun.2008.11.004","volume":"28","author":"V Monforte","year":"2009","unstructured":"Monforte V, Ussetti P, Lopez R, Gavalda J, Bravo C, de Pablo A, Pou L, Pahissa A, Morell F, Roman A. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant. 2009;28(2):170\u20135.","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"1359_CR67","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.healun.2009.11.603","volume":"29","author":"V Monforte","year":"2010","unstructured":"Monforte V, Ussetti P, Gavalda J, Bravo C, Laporta R, Len O, Garcia-Gallo CL, Tenorio L, Sole J, Roman A. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J Heart Lung Transplant. 2010;29(5):523\u201330.","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"1359_CR68","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, et al. Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dise. 2016;63(4):e1\u2013e60.","journal-title":"Clin Infect Dise"},{"issue":"9","key":"1359_CR69","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","volume":"46","author":"BJ Rijnders","year":"2008","unstructured":"Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC, Ruijgrok EJ, Lowenberg B, Vulto A, Lugtenburg PJ, et al. Aerosolized liposomal amphotericin B for the prevention of invasive Pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis. 2008;46(9):1401\u20138.","journal-title":"Clin Infect Dis"},{"issue":"7\u20138","key":"1359_CR70","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s11046-017-0117-9","volume":"182","author":"C Godet","year":"2017","unstructured":"Godet C, Cateau E, Rammaert B, Grosset M, Le Moal G, Beraud G, Martellosio JP, Iriart X, Cadranel J, Roblot F. Nebulized liposomal amphotericin B for treatment of pulmonary infection caused by Hormographiella aspergillata: case report and literature review. Mycopathologia. 2017;182(7\u20138):709\u201313.","journal-title":"Mycopathologia"},{"issue":"3","key":"1359_CR71","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/jamp.2008.0715","volume":"22","author":"L Kuiper","year":"2009","unstructured":"Kuiper L, Ruijgrok EJ. A review on the clinical use of inhaled amphotericin B. J Aerosol Med Pulm Drug Deliv. 2009;22(3):213\u201327.","journal-title":"J Aerosol Med Pulm Drug Deliv"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01359-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-020-01359-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01359-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T23:23:43Z","timestamp":1626737023000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-020-01359-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,20]]},"references-count":71,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["1359"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01359-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,20]]},"assertion":[{"value":"20 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Matteo Bassetti reports grants and personal fees from Pfizer, MSD, and Cidara and personal fees from Astellas and Gilead outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}